A Molecular Tumour Board is now active in IEO for those ‘Troublesome tumours’
Molecular Tumour Boards (MTB) are highly needed to maximise the impact of precision medicine. The purpose of the IEO MTB activity is to translate the most recent scientific research results into personalized therapeutic indications.
The IEO MTB is made up of expert clinicians, pathologists and scientists who have expertise in genetics, sequencing technologies (NGS) and in clinical oncology. At regular meetings, these experts will discuss and analyze tumour genotypes and molecular abnormalities in order to recommend the best specific targeted therapies. "I think MTB’s are so important as they will provide us with the necessary information to make real-world decisions on how to treat those difficult to treat tumours”- says Prof Roberto Orecchia, Scientific director of IEO.
The individual clinical cases that will be discussed in the MTB may include:
- individuals who have a clinical history and for whom it is believed that a molecular profile may have therapeutic implications
- individuals who have performed a molecular profile and in which alterations have been identified
- individuals with specific characteristics or molecular signatures, for which unconventional therapeutic approaches may be beneficial